DETECTING ADALIMUMAB SERUM LEVEL AND ANTI-DRUG ANTIBODIES - FUTURE TOOL IN MONITORING SPONDYLOARTHRITIS PATIENTS?

被引：1
|
作者：
Deaconu, C. [1 ]
Opris, D. [1 ,2 ]
Mazilu, D. [1 ,2 ]
Borangiu, A. [1 ,2 ]
Groseanu, L. [1 ,2 ]
Negru, M. [1 ,2 ]
Constantinescu, C. [1 ,2 ]
Saulescu, I. [1 ,2 ]
Bojinca, V. [1 ,2 ]
Vlad, V. [1 ]
Balanescu, A. [1 ,2 ]
Predeteanu, D. [1 ,2 ]
Ionescu, R. [1 ,2 ]
机构：
[1] SfantaMaria Clin Hosp, Dept Rheumatol & Internal Med, Bucharest, Romania
[2] Univ Med & Pharm Carol Davila, Bucharest, Romania
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-209124.178
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10.06
引用
收藏
页码：A75 / A75
页数：1
相关论文
共 50 条
  • [41] Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
    Chow, V.
    Kaliyaperumal, A.
    Zhang, N.
    Miller, J.
    Mytych, D.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Krishnan, E.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S309 - S309
  • [42] Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies
    Moneo, Mikel
    del Agua, Ainhoa Ruiz
    Ruiz-Arguello, Begona
    Rapun, Noelia
    Nagore, Daniel
    El Hamss, Rachid
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025,
  • [43] Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
    Ulijn, Evy
    den Broeder, Nathan
    Wientjes, Maike
    van Herwaarden, Noortje
    Meek, Inger
    Tweehuysen, Lieke
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 867 - 873
  • [44] Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
    Vallejos, Chelsea
    Cooper, Jennifer
    Pan, Ingrid
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 705 - 707
  • [45] Adalimumab/golimumab/infliximabCytomegalovirus infection, development of anti-drug antibodies and lack of efficacy: case report
    Reactions Weekly, 2021, 1885 (1) : 28 - 28
  • [46] Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    CURRENT DRUG METABOLISM, 2014, 15 (09) : 875 - 881
  • [47] Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Moots, R. J.
    Xavier, Ricardo
    Mok, Chi Chiu
    Rahman, Mahboob U.
    Tsai, Wen-Chan
    Al Maini, Mustafa
    Pavelka, Karel
    Mahgoub, Ehab
    Kotak, Sameer
    Korth-Bradley, Joan
    Pedersen, Ronald
    Mele, Linda
    Shen, Qi
    Vlahos, Bonnie
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [48] Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
    S. C. Sasson
    L. E. Wilkins
    R. A. Watson
    C. Jolly
    O. Brain
    P. Klenerman
    A. Olsson-Brown
    B. P. Fairfax
    Scientific Reports, 11
  • [49] Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis
    Hwang, Jiwon
    Kim, Hye-Mi
    Jeong, Hyemin
    Lee, Jaejoon
    Ahn, Joong Kyong
    Koh, Eun-Mi
    Kang, Eun-Suk
    Cha, Hoon-Suk
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2017, 57 (04) : 311 - 319
  • [50] Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
    Sasson, S. C.
    Wilkins, L. E.
    Watson, R. A.
    Jolly, C.
    Brain, O.
    Klenerman, P.
    Olsson-Brown, A.
    Fairfax, B. P.
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345